Bromide

Bromide

SCHEMBL3523586

Br.BrCCn1ccnc1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788639 0.98
Bromide SCHEMBL3523585 0.93
Bromide SCHEMBL6635203 0.86 TBXAS1 (0.68)
Bromide SCHEMBL10851882 0.85 TBXAS1 (0.72)
SCHEMBL1052113 0.84
Bromide SCHEMBL28914614 0.83 TBXAS1 (0.76)
Bromide SCHEMBL28915325 0.83 TBXAS1 (0.76)
SCHEMBL2473495 0.82 TBXAS1 (0.75)
SCHEMBL4773938 0.82 TBXAS1 (0.75)
SCHEMBL28281551 0.80 TBXAS1 (0.79)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118142582-A Synthesis method and application of bio-fuel catalyst prepared based on Covalent Organic Frameworks (COFs) porous expandable structure 合肥飞木生物科技有限公司 2024-06-07 CN claimed
CN-118142582-A Synthesis method and application of bio-fuel catalyst prepared based on Covalent Organic Frameworks (COFs) porous expandable structure 合肥飞木生物科技有限公司 2024-06-07 CN disclosed
EP-3402784-B1 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2020-03-11 EP disclosed
EP-2984091-B1 DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS LILLY CO ELI (US) 2017-03-01 EP disclosed
US-9550774-B2 Dihydropyrido pyrimidine compounds as autotaxin inhibitors ELI LILLY AND COMPANY (US) 2017-01-24 US disclosed
EP-2984091-A1 DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS Eli Lilly and Company (US) 2016-02-17 EP disclosed
US-20150368240-A1 DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS ELI LILLY AND COMPANY (US) 2015-12-24 US disclosed
WO-2014168824-A1 DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS ELI LILLY AND COMPANY (US) 2014-10-16 WO disclosed
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed
US-20040162299-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE, S.A. 2004-08-19 US disclosed
US-6765006-B2 ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY EURO-CELTIQUE S.A. (LU) 2004-07-20 US disclosed
US-20030033089-A1 Substituted quinazolines and analogs and the use thereof EURO-CELTIQUE S.A. 2003-02-13 US disclosed
US-6465472-B1 SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION EURO-CELTIQUE S.A. (LU) 2002-10-15 US disclosed